HD-OPM Archive
Hashtags

#age

13 posts

Age raises CVD death risk about 19.5x from 65 to 85, far above diabetes or smoking

Dec 18, 2023 · Louis Nervegna ♥ 13 · 💬 20 ↩ 5 Cardiovascular disease: the big picture

Louis compares hazard ratios from the SCORE O.P. risk model for people over 65. A hazard ratio of 1.16 per year of age compounds to about 19.5x higher CVD death risk between 65 and 85, far larger than diabetes, smoking, high blood pressure or LDL. The numbers used are for women; men are similar. (The post also writes this as 19,500%, which is a mislabel of 19.5x.)

JACC statement on geroscience: why aging drives CVD and how to slow cardiovascular aging

Dec 16, 2023 · Louis Nervegna ♥ 11 · 💬 11 ↩ 2 Aging & longevity

Louis calls the JACC Scientific Statement on geroscience the best review so far of why age is the largest CVD risk factor. It argues aging is a common root of chronic disease, explaining multimorbidity, frailty and poorer CVD prognosis in older adults, and describes gerotherapeutic approaches, some already used in CVD care, that could transform management.

Lowering LDL or ApoB is no cure: residual risk persists in every trial; age matters most

Aug 20, 2024 · Louis Nervegna ♥ 25 · 💬 2 LDL, ApoB & lipid panel

The post argues that although aggressive LDL/ApoB lowering reduces risk in many RCTs, considerable residual risk remains in every trial, rising with age. It lists other risk factors (family history, blood pressure, smoking, weight, inflammation, diet, inactivity, insulin resistance/diabetes) and says age is the biggest risk factor, by over 10x versus LDL or ApoB.

Glycation and AGEs in cardiovascular aging: Kapahi on methylglyoxal and the GLYLO suppleme

Dec 18, 2023 · Louis Nervegna ♥ 7 · 💬 9 ↩ 1 Aging & longevity

Louis says he underestimated glycation and AGEs in aging after Pankaj Kapahi's work at the Buck Institute. Kapahi's post explains methylglyoxal as a reactive glycolysis byproduct that drives AGEs and aging, and describes GLYLO, a combination of lipoic acid, nicotinamide, piperine, pyridoxine and thiamine that lowered methylglyoxal and AGEs and extended mouse lifespan even when started late. Louis says Kapahi plans a paper showing it reduces arterial stiffening. Evidence is preclinical and the product is commercial.